Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 3/2008

01-03-2008 | Article

Effects on spectrum and susceptibility patterns of isolates causing bloodstream infection by restriction of fluoroquinolone prophylaxis in a hematology–oncology unit

Authors: T. Saito, S. Yoshioka, Y. Iinuma, S. Takakura, N. Fujihara, T. Ichinohe, T. Ishikawa, T. Uchiyama, S. Ichiyama

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 3/2008

Login to get access

Abstract

The emergence of fluoroquinolone-resistant gram-negative organisms has been demonstrated in patients given fluoroquinolone prophylaxis. To prevent increases in resistant bacteria, we restricted prophylactic use of fluoroquinolones. The spectrum and susceptibility patterns of isolates causing bloodstream infection (BSI) were assessed in patients receiving chemotherapy during periods of routine prophylaxis (period A: October 2001 to May 2003) and restricted prophylaxis (period B: June 2003 to January 2005). The total number of patients receiving chemotherapy was 442 during period A and 365 during period B. No significant differences were seen between periods with respect to patient characteristics. BSI was identified in 42 patients (44 episodes) during period A and 69 patients (74 episodes) during period B. Incidence of BSI increased significantly from 10.0% (44/442) during period A to 20.3% (74/365) during period B (P < 0.0001). Rate of Enterobacteriaceae BSI increased significantly, from 2.0% (9/442) during period A to 8.2% (30/365) during period B (P < 0.0001). For all BSI episodes, the proportion of BSI with gram-positive cocci decreased from 63.6% (28/44) during period A to 44.6% (33/74) during period B (P = 0.045), while the proportion of BSI with Enterobacteriaceae increased from 20.5% (9/44) to 40.5% (30/74) (P < 0.0001). The proportion of fluoroquinolone-resistant Enterobacteriaceae BSI for all Enterobacteriaceae BSI decreased from 75% (9/12) during period A to 17% (5/30) during period B (P = 0.0078). Restriction of fluoroquinolone prophylaxis affects the etiology of BSI and reduces the proportion of drug-resistant organisms.
Literature
1.
go back to reference Murphy M, Brown AE, Sepkowitz KA, Bernard EM, Kiehn TE, Armstrong D (1997) Fluoroquinolone prophylaxis for the prevention of bacterial infections in patients with cancer—is it justified? Clin Infect Dis 25:346–348PubMed Murphy M, Brown AE, Sepkowitz KA, Bernard EM, Kiehn TE, Armstrong D (1997) Fluoroquinolone prophylaxis for the prevention of bacterial infections in patients with cancer—is it justified? Clin Infect Dis 25:346–348PubMed
2.
go back to reference Cruciani M, Rampazzo R, Malena M, Lazzarini L, Todeschini G, Messori A, Concia E (1995) Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin Infect Dis 23:795–805 Cruciani M, Rampazzo R, Malena M, Lazzarini L, Todeschini G, Messori A, Concia E (1995) Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin Infect Dis 23:795–805
3.
go back to reference Engels EA, Lau J, Barza M (1999) Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol 16:1179–87 Engels EA, Lau J, Barza M (1999) Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol 16:1179–87
4.
go back to reference Klastersky J (1996) Prevention of infection in neutropenic cancer patients. Curr Opin Oncol 8:270–278PubMed Klastersky J (1996) Prevention of infection in neutropenic cancer patients. Curr Opin Oncol 8:270–278PubMed
5.
go back to reference Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G, Allione B, D’Antonio D, Buelli M, Nosari AM, Cilloni D, Zuffa E, Cantaffa R, Specchia G, Amadori S, Fabbiano F, Deliliers GL, Lauria F, Foa R, Del Favero A; Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) Infection Program (2005) Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 353:977–987PubMedCrossRef Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G, Allione B, D’Antonio D, Buelli M, Nosari AM, Cilloni D, Zuffa E, Cantaffa R, Specchia G, Amadori S, Fabbiano F, Deliliers GL, Lauria F, Foa R, Del Favero A; Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) Infection Program (2005) Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 353:977–987PubMedCrossRef
6.
go back to reference Cullen M, Steven N, Billingham L, Gaunt C, Hastings M, Simmonds P, Stuart N, Rea D, Bower M, Fernando I, Huddart R, Gollins S, Stanley A; Simple Investigation in Neutropenic Individuals of the Frequency of Infection after Chemotherapy +/− Antibiotic in a Number of Tumours (SIGNIFICANT) Trial Group (2005) Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 353:988–998PubMedCrossRef Cullen M, Steven N, Billingham L, Gaunt C, Hastings M, Simmonds P, Stuart N, Rea D, Bower M, Fernando I, Huddart R, Gollins S, Stanley A; Simple Investigation in Neutropenic Individuals of the Frequency of Infection after Chemotherapy +/− Antibiotic in a Number of Tumours (SIGNIFICANT) Trial Group (2005) Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 353:988–998PubMedCrossRef
7.
go back to reference van de Wetering MD, de Witte MA, Kremer LC, Offringa M, Scholten RJ, Caron HN (2005) Efficacy of oral prophylactic antibiotics in neutropenic afebrile oncology patients: a systematic review of randomised controlled trials. Eur J Cancer 41:1372–1382PubMedCrossRef van de Wetering MD, de Witte MA, Kremer LC, Offringa M, Scholten RJ, Caron HN (2005) Efficacy of oral prophylactic antibiotics in neutropenic afebrile oncology patients: a systematic review of randomised controlled trials. Eur J Cancer 41:1372–1382PubMedCrossRef
8.
go back to reference Gafter-Gvili A, Fraser A, Paul M, Leibovici L (2005) Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 142:979–995PubMed Gafter-Gvili A, Fraser A, Paul M, Leibovici L (2005) Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 142:979–995PubMed
9.
go back to reference Reuter S, Kern WV, Sigge A, Dohner H, Marre R, Kern P, von Baum H (2005) Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies. Clin Infect Dis 40:1087–1093PubMedCrossRef Reuter S, Kern WV, Sigge A, Dohner H, Marre R, Kern P, von Baum H (2005) Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies. Clin Infect Dis 40:1087–1093PubMedCrossRef
10.
go back to reference Cometta A, Calandra T, Bille J, Glauser MP (1994) Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. N Engl J Med 330: 1240–1241PubMedCrossRef Cometta A, Calandra T, Bille J, Glauser MP (1994) Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. N Engl J Med 330: 1240–1241PubMedCrossRef
11.
go back to reference Carratala J, Fernandez-Sevilla A, Tubau F, Callis M, Gudiol F (1995) Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have receiving prophylactic norfloxacin. Clin Infect Dis 20:557–560PubMed Carratala J, Fernandez-Sevilla A, Tubau F, Callis M, Gudiol F (1995) Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have receiving prophylactic norfloxacin. Clin Infect Dis 20:557–560PubMed
12.
go back to reference Kern WV, Andriof E, Oethinger M, Kern P, Hacker J, Marre R (1994) Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother 38:681–687PubMed Kern WV, Andriof E, Oethinger M, Kern P, Hacker J, Marre R (1994) Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother 38:681–687PubMed
13.
go back to reference Zinner SH (1999) Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis 29:490–494PubMedCrossRef Zinner SH (1999) Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis 29:490–494PubMedCrossRef
14.
go back to reference Baum HV, Franz U, Geiss HK (2000) Prevalence of ciprofloxacin-resistant Escherichia coli in hematologic-oncologic patients. Infection 28:278–281PubMedCrossRef Baum HV, Franz U, Geiss HK (2000) Prevalence of ciprofloxacin-resistant Escherichia coli in hematologic-oncologic patients. Infection 28:278–281PubMedCrossRef
15.
go back to reference Hughes WT, Armstrong D, Bodey GP, Brown AE, Edwards JE, Feld R, Pizzo P, Rolston KV, Shenep JL, Young LS (1997) 1997 Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis 25:551–575PubMedCrossRef Hughes WT, Armstrong D, Bodey GP, Brown AE, Edwards JE, Feld R, Pizzo P, Rolston KV, Shenep JL, Young LS (1997) 1997 Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis 25:551–575PubMedCrossRef
16.
go back to reference Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, Young LS (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730–751PubMedCrossRef Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, Young LS (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730–751PubMedCrossRef
17.
go back to reference Freifeld AG, Baden LR, Brown AE, Elting LS, Gelfand M, Greene LN, Ito JI, King E, Marcucci G, Montoya JG, Morris A, Noskin G, Rolston K, Schott AF, Segal B, Talcott JA (2004) Fever and neutropania. J National Comprehensive Cancer Network 23:390–432 Freifeld AG, Baden LR, Brown AE, Elting LS, Gelfand M, Greene LN, Ito JI, King E, Marcucci G, Montoya JG, Morris A, Noskin G, Rolston K, Schott AF, Segal B, Talcott JA (2004) Fever and neutropania. J National Comprehensive Cancer Network 23:390–432
18.
go back to reference Yoshida M, Ohno R (2004) Current antimicrobial usage for the management of infections in leukemic patients in Japan: results of a survey. Clin Infect Dis 39(Suppl 1):S11–14PubMedCrossRef Yoshida M, Ohno R (2004) Current antimicrobial usage for the management of infections in leukemic patients in Japan: results of a survey. Clin Infect Dis 39(Suppl 1):S11–14PubMedCrossRef
19.
go back to reference National Committee for Clinical Laboratory Standards (2000) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. NCCLS approved standard M7–A5. National Committee for Clinical Laboratory Standards, Wayne National Committee for Clinical Laboratory Standards (2000) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. NCCLS approved standard M7–A5. National Committee for Clinical Laboratory Standards, Wayne
20.
go back to reference Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM (1998) CDC definitions for nosocomial infections, 1988. Am J Infect Control 16:128–140CrossRef Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM (1998) CDC definitions for nosocomial infections, 1988. Am J Infect Control 16:128–140CrossRef
22.
go back to reference Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B, Rolston K, Talcott J (2000) The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18:3038–3051PubMed Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B, Rolston K, Talcott J (2000) The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18:3038–3051PubMed
23.
go back to reference Vincent AL, Price R, Field T, Greene JN, Sandin RL (2005) Addition of fluoroquinolone prophylaxis to a blood and marrow transplant unit reduces gram-negative infections. Cancer Control 12:203–206PubMed Vincent AL, Price R, Field T, Greene JN, Sandin RL (2005) Addition of fluoroquinolone prophylaxis to a blood and marrow transplant unit reduces gram-negative infections. Cancer Control 12:203–206PubMed
Metadata
Title
Effects on spectrum and susceptibility patterns of isolates causing bloodstream infection by restriction of fluoroquinolone prophylaxis in a hematology–oncology unit
Authors
T. Saito
S. Yoshioka
Y. Iinuma
S. Takakura
N. Fujihara
T. Ichinohe
T. Ishikawa
T. Uchiyama
S. Ichiyama
Publication date
01-03-2008
Publisher
Springer-Verlag
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 3/2008
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-007-0428-8

Other articles of this Issue 3/2008

European Journal of Clinical Microbiology & Infectious Diseases 3/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.